

Suzanne L Parker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5326944/publications.pdf>

Version: 2024-02-01

48
papers

816
citations

430874

18
h-index

552781

26
g-index

51
all docs

51
docs citations

51
times ranked

1043
citing authors

#	ARTICLE	IF	CITATIONS
1	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 289-293.	2.5	63
2	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	3.2	59
3	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. <i>Bioanalysis</i> , 2015, 7, 2585-2595.	1.5	45
4	Optimizing dosing of antibiotics in critically ill patients. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 497-504.	3.1	41
5	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	35
6	Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?. <i>Clinical Therapeutics</i> , 2016, 38, 1961-1975.	2.5	31
7	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. <i>Bioanalysis</i> , 2016, 8, 2235-2242.	1.5	29
8	A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 39-45.	2.8	28
9	Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	27
10	Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 715-721.	1.9	25
11	The use and risks of antibiotics in critically ill patients. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 667-678.	2.4	25
12	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. <i>Bioanalysis</i> , 2018, 10, 407-423.	1.5	25
13	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 509-514.	2.8	23
14	A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 324-333.	2.8	23
15	Effect of naproxen co-administration on valproate disposition. <i>Biopharmaceutics and Drug Disposition</i> , 2000, 21, 235-242.	1.9	22
16	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans. <i>Biomedical Chromatography</i> , 2016, 30, 872-879.	1.7	22
17	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. <i>Critical Care</i> , 2019, 23, 205.	5.8	22
18	Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. <i>Epilepsy Research</i> , 2000, 41, 259-268.	1.6	21

#	ARTICLE	IF	CITATIONS
19	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	21
20	Is there a role for microsampling in antibiotic pharmacokinetic studies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 601-614.	3.3	20
21	An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Bioanalysis</i> , 2017, 9, 911-924.	1.5	17
22	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 201-210.	4.4	17
23	Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. <i>Anesthesiology</i> , 2019, 131, 344-355.	2.5	17
24	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2021, 60, 655-664.	3.5	16
25	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	15
26	Prophylactic Cefazolin Dosing in Women With Body Mass Index $\geq 35 \text{ kg}\cdot\text{m}^{-2}$ Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. <i>Anesthesia and Analgesia</i> , 2020, 131, 199-207.	2.2	14
27	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 288-292.	2.8	12
28	Kidney transplant recipient's perceptions of blood testing through microsampling and venepuncture. <i>Bioanalysis</i> , 2020, 12, 873-881.	1.5	12
29	A validated LC-MS/MS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7831-7840.	3.7	11
30	An UHPLC-MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. <i>Bioanalysis</i> , 2015, 7, 2311-2319.	1.5	9
31	Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 274-284.	2.3	8
32	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 17.	1.9	7
33	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2155-2162.	3.7	7
34	Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. <i>Journal of Pharmaceutical Analysis</i> , 2018, 8, 407-412.	5.3	6
35	Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. <i>Anesthesia and Analgesia</i> , 2019, 129, 701-708.	2.2	6
36	Microsampling to support pharmacokinetic clinical studies in pediatrics. <i>Pediatric Research</i> , 2022, 91, 1557-1561.	2.3	6

#	ARTICLE	IF	CITATIONS
37	Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. <i>Journal of Critical Care</i> , 2018, 47, 15-20.	2.2	5
38	Characterisation of 40µg/ml and 100µg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 93-99.	2.6	4
39	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 921-933.	2.3	4
40	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	4
41	The role of antibiotic pharmacokinetic studies performed post-licensing. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106165.	2.5	3
42	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 4483-4491.	3.7	2
43	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. <i>Antibiotics</i> , 2021, 10, 100.	3.7	2
44	A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. <i>Biomedical Chromatography</i> , 2017, 31, e4030.	1.7	1
45	Antithrombin Dosing Guidelines in Children Underestimate Dose Needed for Plasma Level Increase. <i>Pediatric Critical Care Medicine</i> , 2020, 21, 746-752.	0.5	1
46	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106513.	2.5	1
47	Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation. <i>Antibiotics</i> , 2022, 11, 434.	3.7	1
48	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2227-2237.	3.0	1